Silence Therapeutics PLC (SLN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Silence Therapeutics PLC (SLN) has a cash flow conversion efficiency ratio of -0.147x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.89 Million) by net assets ($74.06 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Silence Therapeutics PLC (SLN) net asset quality to measure how much of total assets are equity-financed.
Silence Therapeutics PLC - Cash Flow Conversion Efficiency Trend (1995–2024)
This chart illustrates how Silence Therapeutics PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of Silence Therapeutics PLC to evaluate the quality of earnings relative to operating cash generation.
Silence Therapeutics PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Silence Therapeutics PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tyro Payments Ltd
AU:TYR
|
0.646x |
|
Taeyoung Engineering & Construction Co.,Ltd.
KO:009410
|
-0.073x |
|
Lime Technologies AB (publ)
ST:LIME
|
0.132x |
|
Guangdong New Grand Long Packing Co Ltd
SHE:002836
|
-0.084x |
|
Shanghai No1 Pharmacy Co Ltd
SHG:600833
|
-0.026x |
|
Pinlive Foods Co Ltd
SHE:300892
|
0.009x |
|
VT GMP Co.Ltd
KQ:018290
|
-0.043x |
|
Yunnan Metropolitan Real Estate Development Co Ltd
SHG:600239
|
0.133x |
Annual Cash Flow Conversion Efficiency for Silence Therapeutics PLC (1995–2024)
The table below shows the annual cash flow conversion efficiency of Silence Therapeutics PLC from 1995 to 2024. For the full company profile with market capitalisation and key ratios, see SLN market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $134.02 Million | $-67.64 Million | -0.505x | +71.79% |
| 2023-12-31 | $21.99 Million | $-39.35 Million | -1.789x | +30.77% |
| 2022-12-31 | $22.07 Million | $-57.04 Million | -2.584x | -339.89% |
| 2021-12-31 | $8.53 Million | $9.19 Million | 1.077x | +190.57% |
| 2020-12-31 | $9.06 Million | $-10.78 Million | -1.190x | -1540.18% |
| 2019-12-31 | $20.91 Million | $1.73 Million | 0.083x | +117.28% |
| 2018-12-31 | $35.05 Million | $-16.76 Million | -0.478x | -160.74% |
| 2017-12-31 | $52.35 Million | $-9.60 Million | -0.183x | +1.30% |
| 2016-12-31 | $54.18 Million | $-10.07 Million | -0.186x | -35.99% |
| 2015-12-31 | $60.43 Million | $-8.26 Million | -0.137x | +59.91% |
| 2014-12-31 | $27.76 Million | $-9.46 Million | -0.341x | -39.08% |
| 2013-12-31 | $27.58 Million | $-6.76 Million | -0.245x | +19.02% |
| 2012-12-31 | $16.12 Million | $-4.88 Million | -0.303x | -90.52% |
| 2011-12-31 | $32.18 Million | $-5.11 Million | -0.159x | +51.43% |
| 2010-12-31 | $32.27 Million | $-10.55 Million | -0.327x | +37.45% |
| 2009-12-31 | $8.89 Million | $-4.65 Million | -0.523x | -0.67% |
| 2008-12-31 | $13.44 Million | $-6.98 Million | -0.519x | -139.48% |
| 2007-12-31 | $17.68 Million | $-3.83 Million | -0.217x | +15.48% |
| 2006-12-31 | $15.71 Million | $-4.03 Million | -0.257x | -44.68% |
| 2005-12-31 | $15.69 Million | $-2.78 Million | -0.177x | +83.24% |
| 2004-12-31 | $2.34 Million | $-2.48 Million | -1.058x | -169.58% |
| 2003-12-31 | $5.18 Million | $-2.04 Million | -0.393x | -59.14% |
| 2002-12-31 | $7.46 Million | $-1.84 Million | -0.247x | +3.33% |
| 2001-12-31 | $8.95 Million | $-2.28 Million | -0.255x | +0.60% |
| 2000-12-31 | $11.14 Million | $-2.86 Million | -0.257x | -108.48% |
| 1999-12-31 | $9.21 Million | $-1.13 Million | -0.123x | +77.21% |
| 1998-12-31 | $3.34 Million | $-1.81 Million | -0.540x | -64.85% |
| 1997-12-31 | $4.63 Million | $-1.52 Million | -0.328x | -188.07% |
| 1996-12-31 | $6.39 Million | $-727.00K | -0.114x | +58.72% |
| 1995-12-31 | $2.76 Million | $-761.00K | -0.276x | -- |
About Silence Therapeutics PLC
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated … Read more